Cochleates: New Lipid-Based Drug Delivery System

References

• Zarif L., Graybill J. R., Perlin D., Najvar L., Bocanegra R., Mannino R. J. Antifungal activity of amphotericin B cochleates against Candida albicans in a mouse model. Antimicrob Agents Chemother 2000; 44(6)1463–1469
   PubMed Web of Science ®Google Scholar
• Graybill J. R., Najvar L., Bocanegra R., Scolpino A., Mannino R. J., Zarif L. A new lipid vehicle for amphotericin B, abstract. 39th ICAAC, San Francisco, 26–29 September, 1999, 583
   Google Scholar
• Santangelo R., Paderu P., Delmas G., Chen ZW, Mannino R. J., Zarif L., Perlin D. Oral efficacy of cochleate-amphotericin B (CAMB) in a mouse model with systemic candidiasis. Antimicrob Agents and Chemother 2000; 44(9)2356–2360
   PubMed Web of Science ®Google Scholar
• Zarif L., Jin T., Scolpino A., Mannino R. J. Are cochleates the new lipid-based carrier for oral drug delivery, abstract. 39th ICAAC, San Francisco, 26–29 September, 1999, 344
   Google Scholar
• Zarif L., Mannino R. J. Cochleates, lipid-based vehicles for gene delivery- Concept, Achievements and Future Development. Cancer Gene Therapy: Past Achievements and Future Challenges, N. Habib. Plenum Publishing Company. 2000; 83–94, Chapter 9
   Google Scholar
• Mannino R. J., Gould-Fogerite S. Antigen cochleate formulations for oral and systemic vaccination. New Generation Vaccines, 2^nd Ed, M. M. Levine. Marcel Dekker, Inc., New York, NY 1997; 229–239, Chapter 18
   Google Scholar
• Edwards J. E., Jr., Filler S. G. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis 1992; 14: S106–S113, Suppl 1
   PubMed Web of Science ®Google Scholar
• Kaloyanides G. J. Antibiotic-related nephrotoxicity. Nephrol Dial Transplant 1994; 9: 130–134, Suppl 4
   PubMed Web of Science ®Google Scholar
• Sabra R., Branch R. A. Amphotericin B nephrotoxicity. Drug Saf 1990; 5(2)94–108
   PubMed Web of Science ®Google Scholar
• Sawaya B. P., Briggs J. P., Schnermann J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6(2)154–164
   PubMed Web of Science ®Google Scholar
• Adle-Moore J. P., Proffitt R. T. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993; 3: 429–450
   Google Scholar
• Adle-Moore J. P., Chiang S. M., Satorius A., Guerra D., McAndrews B., McManus E. J., Proffitt R. T. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother 1991; 28: 63–71, (Suppl B)
   PubMedGoogle Scholar
• Walsh T. J., Yeldandi V., McEvoy M., Gonzales C., Chanock S., Freifeld A., Seibel N. I., Whitcomb P. O., Jarosinski P., Boswell G., Bekersky I., Alak A., Buell D., Barret J., Wilson W. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42(9)2391–2398
   PubMed Web of Science ®Google Scholar
• Janoff A. S., Perkin W. R., Saletan S. L., Swenson C. E. Amphotericin B complex (ABLC™); a molecular rationale for the attenuation of amphotericin B related toxicity. J Liposome Res 1993; 3(3)451–471
   Google Scholar
• Guo L. S. S., Fielding R. M., Lasic D. L., Hamilton R. L., Mufson D. Novel antifungal drug delivery: Stable amphotericin B-cholesteryl sulfate discs. International Journal of Pharmaceutics 1991; 75: 45–54
   Web of Science ®Google Scholar
• Wong-Beringer A., Jacobs R. A., Guglielmo B. J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27(3)603–618
   PubMed Web of Science ®Google Scholar
• Robinson R. F., Nahata M. C. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther 1999; 24(4)249–257
   PubMed Web of Science ®Google Scholar
• Bekersky I., Fielding R. M., Buell D., Lawrence I. Lipid-based amphotericin B formulations: from animals to man. PSTT 1999; 2(6)230–236
   PubMedGoogle Scholar
• Zarif L., Mannino R. J. Cochleate cylinders: A next generation lipid-based drug delivery system. J Controlled Rel, (submitted)
   Google Scholar
• Zarif L., Jin T., Segarra I., Mannino R. J. Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of pharmaceutical agents. PCT application filed, 1/22/2000
   Google Scholar
• Zarif L., Mannino R. J. Cochleate lipid assemblies for oral and systemic delivery of drugs. Abstract AAPS 2000 Annual meeting, Indianapolis, IN, October 29-November 2, 2000
   Google Scholar
• Zarif L., Chen Z. W., Tan F., Mannino R. J. Cochleate assemblies: An ideal vehicle for small and macromolecules. Abstract AAPS Eastern Regional Meeting, Parsippany, New Jersey, June 22–23, 2000
   Google Scholar
• Grit M., Crommelin D. J. Chemical stability of liposomes: implications for their physical stability. Chem Phys Lipids 1993; 64(1–3)3–18
   PubMed Web of Science ®Google Scholar
• Porter C. J.H. Drug delivery to the lymphatic system. Therapeutic Drug Carrier Systems 1997; 14(4)333–393
   PubMed Web of Science ®Google Scholar
• Villardita C., Grioli S., Salmeri G., Nicoletti F., Pennisi G. Multicenter clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J 1987; 24: 84–93
   Google Scholar
• Crook T. H., Tinkenberg J., Yesavage J., Petrie W., Nunzi M. G., Massari D. C. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991; 41: 644–649
   PubMed Web of Science ®Google Scholar
• Engel R. R., Satzger W., Gunther W., Kathmann N., Bove D., Gerke S., Munch U., Hippius H. Double-blind cross over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992; 2: 149–155
   PubMedGoogle Scholar
• Daneshmend T. K., Warnock D. W. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokin 1983; 8: 17–42
   PubMed Web of Science ®Google Scholar